Stockscreener 앱 받기
6.01
2.04%
0.12
시간 외 거래:
6.01
전일 마감가:
$5.89
열려 있는:
$6
하루 거래량:
52,397
Relative Volume:
0.53
시가총액:
$96.28M
수익:
-
순이익/손실:
$-14.72M
주가수익비율:
-2.1237
EPS:
-2.83
순현금흐름:
$-7.41M
1주 성능:
-9.08%
1개월 성능:
+6.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$5.75
$6.2625
1주일 범위
$5.52
$6.65
52주 변동 폭
$4.66
$7.00
Alpha Cognition Inc Stock (ACOG) Company Profile
명칭
Alpha Cognition Inc
전화
(858) 344-4375
주소
1200-750 W PENDER ST, VANCOUVER
ACOG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACOG
Alpha Cognition Inc
|
6.01 | 96.28M | 0 | -14.72M | -7.41M | -2.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alpha Cognition Inc 주식(ACOG)의 최신 뉴스
Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG) - Newsfile
Stonegate Capital Partners Initiates Coverage on Alpha Cognition's Innovative Alzheimer's Therapy ZUNVEYL - Citybuzz
OTC Markets Group Announces Quarterly Index Performance and Rebalancing - The Manila Times
OTC Markets Group Announces Quarterly Index Performance and Rebalancing - GlobeNewswire Inc.
Alpha Cognition to delist from Canadian Securities Exchange - MSN
Moves at FDA, NIH - BioCentury
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL - BioSpace
Zunveyl: An Improved Alzheimer's Drug With Fewer Side Effects Will Be Available Soon - Verywell Health
Alpha Cognition makes strategic personnel appointments to support ZUNVEYL launch - TipRanks
Alpha Cognition Expands Leadership Team Ahead of Landmark Alzheimer's Drug Launch in 2025 - StockTitan
Top Dividend Stocks For Reliable Income In January 2025 - Simply Wall St
Deal Watch: Lilly Looks To Alchemab’s ‘Resilient’ Antibodies To Take On ALS - News & Insights
Alpha Cognition Inks $44M Deal With China's CMS to License Alzheimer's Drug in Asia and Beyond - dallasinnovates.com
Alpha Cognition licenses ZUNVEYL in Asia and Oceania By Investing.com - Investing.com Canada
ACOG News Today | Why did Alpha Cognition stock go up today? - MarketBeat
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China - AOL
China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type - The Manila Times
Alpha Cognition licenses ZUNVEYL in Asia and Oceania - Investing.com India
China Medical System Secures Rights to Alzheimer’s Drug ZUNVEYL - TipRanks
Alpha Cognition Lands $44M ZUNVEYL Licensing Deal for Massive Asian Alzheimer's Market - StockTitan
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call - BioSpace
Alpha Cognition Sets Launch Strategy Call for Breakthrough Alzheimer's Drug ZUNVEYL - StockTitan
Alpha Cognition files to sell 1.45M common shares for holders - MSN
Alpha Cognition announces private sale of equity securities - Investing.com
Alpha Cognition stock hits 52-week low at $5.3 amid market challenges - Investing.com Australia
Alpha Cognition Raises $52.8 Million in Stock Offering - TipRanks
Alpha Cognition Raises $52.8M in Nasdaq IPO, Strengthens Alzheimer's Drug Commercialization Plans - StockTitan
Alpha Cognition Reports Promising Data for Brain Injury Drug - TipRanks
CSE Bulletin: DelistAlpha Cognition Inc. (ACOG) - Newsfile
Alpha Cognition Announces Voluntary Delisting from CSE - The Globe and Mail
Alpha Cognition sees promising data for military-related trauma treatment - MSN
Alpha Cognition Exits CSE to Focus on Nasdaq Listing, Streamlines Trading Strategy - StockTitan
Alpha Cognition Inc (ACOG-CN) QuotePress Release - The Globe and Mail
Alpha Cognition sees promising data for military-related trauma treatment | 2024-12-11 | Investing News - Stockhouse Publishing
Alpha Cognition Announces Positive Interim Pre-Clinical Data for Alpha-1062 Use in A Military Relevant Model of Repetitive Mild Traumatic Brain Injury - Marketscreener.com
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury - BioSpace
Opening Day: Invizyne Technologies jumps after IPO - MSN
Alpha Cognition Inc. announced that it expects to receive $46.149996 million in funding - Marketscreener.com
Alpha Cognition announces equity offering and warrant adjustments - Investing.com
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update - BioSpace
Alpha cognition CEO Michael McFadden acquires shares worth $14,996 - Investing.com India
Alpha Cognition director Leonard Mertz acquires $49,996 in shares By Investing.com - Investing.com South Africa
Alpha cognition director John Havens buys $24,995 in common shares By Investing.com - Investing.com Nigeria
Alpha Cognition director Leonard Mertz acquires $49,996 in shares - Investing.com
Alpha cognition CEO Michael McFadden acquires shares worth $14,996 By Investing.com - Investing.com UK
Alpha Cognition's FDA-Approved Alzheimer's Drug ZUNVEYL Set for 2025 Launch - StockTitan
Alpha Cognition Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Alpha Cognition Inc (ACOGF) Quarterly 10-Q Report - Quartz
Alpha Cognition prices $50M stock offering - MSN
Canada market stock losers: Tidewater Renewables Ltd. looses 12.43% while Rektron Group Inc dips by 10.33% during mid day trading - Business Upturn
Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing - Business Wire
Alpha Cognition Inc (ACOG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.02%
0.32%
자본화:
|
볼륨(24시간):